Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Wegovy can cause side effects ... used for weight loss and weight management in: adults and children ages 12 years and older with obesity adults who are overweight and have at least one weight ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

The development of GLP-1 drugs, such as Wegovy ... muscle loss than expected for the achieved decline in weight. How do we know if muscle loss on GLP-1 drugs is unhealthy? One of the obstacles ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

IT’S NOT ALL about shedding pounds and curbing hunger. GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user.

BMI requirement: The FDA has approved Wegovy for those who have a body mass index (BMI) of 30 or higher. For example, that could mean weighing more than 180 pounds ... Rybelsus is usually one of the ...

And as mentioned, weight loss is an off-label use. Other brand names for semaglutide you might have heard of include Wegovy ... (body mass index) of 30 or more or a BMI of 27 or more with at least ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...